Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial

BACKGROUND: At the time of the initial analysis of overall survival (OS) for the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) randomized, double-blind, phase III trial, approximately 50% of patients had died. A final analysis of OS was subsequently planned for when 75% o...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Leo, Angelo Di, Jerusalem, Guy, Petruzelka, Lubos, Torres, Roberto, Bondarenko, Igor N., Khasanov, Rustem, Verhoeven, Didier, Pedrini, José L., Smirnova, Iya, Lichinitser, Mikhail R., Pendergrass, Kelly, Malorni, Luca, Garnett, Sally, Rukazenkov, Yuri, Martin, Miguel
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3906991/
https://ncbi.nlm.nih.gov/pubmed/24317176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt337
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires